Virtual Screening Approach and Investigation of Structure-Activity Relationships To Discover Novel Bacterial Topoisomerase Inhibitors Targeting Gram-Positive and Gram-Negative Pathogens.Magaro, G., Prati, F., Garofalo, B., Corso, G., Furlotti, G., Apicella, C., Mangano, G., D'Atanasio, N., Robinson, D., Di Giorgio, F.P., Ombrato, R.
(2019) J Med Chem 62: 7445-7472
- PubMed: 31276392
- DOI: https://doi.org/10.1021/acs.jmedchem.9b00394
- Primary Citation of Related Structures:
- PubMed Abstract:
Bacterial resistance is increasing rapidly, requiring urgent identification of new antibacterial drugs that are effective against multidrug-resistant pathogens. Novel bacterial topoisomerase inhibitors (NBTIs) provide a new strategy for investigating the well-validated DNA gyrase and topoisomerase IV targets while preventing cross-resistance issues. On this basis, starting from a virtual screening campaign and subsequent structure-based hit optimization guided by X-ray studies, a novel class of piperazine-like NBTIs with outstanding enzymatic activity against Staphylococcus aureus and Escherichia coli DNA gyrase and topoisomerase IV was identified. Notably, compounds (±)-33 , (±)-35 , and (±)-36 with potent and balanced multitarget enzymatic profiles exhibited excellent efficacy against selected Gram-positive and Gram-negative pathogens, as well as clinically relevant resistant strains. Overall, the new NBTI chemotype described herein, owing to the broad-spectrum antibacterial activity and favorable in vitro safety profile, might serve as a basis for the development of novel treatments against serious infections.
Schrodinger , 120 West 45th Street , New York , New York 10036 , United States.